We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $962M
1-Year Est. Return 524.64%
This Fund
S&P 500
This Quarter Est. Return
+26.72%
1 Year Est. Return
+524.64%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.08%
10 Year Est. Return
–
AUM
$980M
AUM Growth
+$260M
Cap. Flow
+$316M
Cap. Flow %
32.2%
Top 10 Hldgs %
50.1%
Holding
93
New
25
Increased
16
Reduced
28
Closed
20

Top Buys

Rank Stock Value
1
ZBIO
Zenas BioPharma
ZBIO
+$25.5M
2
GLUE icon
Monte Rosa Therapeutics
GLUE
+$18.6M
3
ASND icon
Ascendis Pharma A/S
ASND
+$16.9M
4
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$16.5M
5
IMNM icon
Immunome
IMNM
+$16.1M

Top Sells

Rank Stock Value
1
ABVX
Abivax
ABVX
+$14.2M
2
CGON icon
CG Oncology
CGON
+$11M
3
VRDN icon
Viridian Therapeutics
VRDN
+$10.8M
4
PFE icon
Pfizer
PFE
+$10.4M
5
AVTX icon
Avalo Therapeutics
AVTX
+$9.52M

Sector Composition

Rank Sector Weight
1 Healthcare 85.36%
2 Financials 1.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XNTK icon
1
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2.27B
$105M 10.75%
+825,000
New +$225M
KALV
2
DELISTED
KalVista Pharmaceuticals
KALV
$57.9M 5.91%
2,876,407
+449,289
+19% +$7.24M
DNTH icon
3
Dianthus Therapeutics
DNTH
$6.13B
$54.9M 5.61%
654,746
-95,390
-13% -$5.52M
COGT icon
4
Cogent Biosciences
COGT
$6.47B
$50.6M 5.16%
1,314,189
+68,935
+6% +$2.55M
CELC icon
5
Celcuity
CELC
$4.22B
$40.9M 4.17%
357,903
-17,229
-5% -$1.88M
IMNM icon
6
Immunome
IMNM
$3B
$40.5M 4.13%
1,850,278
+724,068
+64% +$16.1M
KOD icon
7
Kodiak Sciences
KOD
$2.5B
$37.8M 3.86%
991,930
-31,192
-3% -$806K
NUVL
8
DELISTED
Nuvalent
NUVL
$36.4M 3.71%
354,914
+43,484
+14% +$4.43M
ABVX
9
Abivax
ABVX
$10.6B
$33.7M 3.44%
302,530
-119,663
-28% -$14.2M
GLUE icon
10
Monte Rosa Therapeutics
GLUE
$1.35B
$32.9M 3.36%
2,002,040
+972,974
+95% +$18.6M
ERAS icon
11
Erasca
ERAS
$6.25B
$30M 3.06%
1,851,812
+534,228
+41% +$6.31M
ASND icon
12
Ascendis Pharma A/S
ASND
$16.2B
$28.5M 2.91%
124,658
+75,430
+153% +$16.9M
URGN icon
13
UroGen Pharma
URGN
$2.34B
$27M 2.76%
1,503,045
-235,776
-14% -$4.73M
RYTM icon
14
Rhythm Pharmaceuticals
RYTM
$7.99B
$26.6M 2.72%
306,000
+170,050
+125% +$16.5M
PRAX icon
15
Praxis Precision Medicines
PRAX
$10.3B
$23.1M 2.35%
71,552
-10,913
-13% -$3.38M
ZBIO
16
Zenas BioPharma
ZBIO
$1.84B
$22.2M 2.27%
+1,135,935
New +$25.5M
SNDX icon
17
Syndax Pharmaceuticals
SNDX
$1.7B
$20.8M 2.12%
888,987
+246,088
+38% +$5.35M
CNTA
18
DELISTED
Centessa Pharmaceuticals
CNTA
$18.5M 1.89%
466,345
+8,142
+2% +$208K
SRRK icon
19
Scholar Rock
SRRK
$6.46B
$16.7M 1.7%
+339,613
New +$15.2M
ALKS icon
20
Alkermes
ALKS
$8.3B
$16.3M 1.66%
+460,314
New +$14.3M
ORIC icon
21
Oric Pharmaceuticals
ORIC
$1.42B
$13.9M 1.42%
1,100,010
-16,594
-1% -$188K
IRON icon
22
Disc Medicine
IRON
$3.07B
$12.5M 1.28%
+196,028
New +$13.6M
HLXC
23
Helix Acquisition Corp III
HLXC
$238M
$12.3M 1.25%
+1,208,986
New +$12.4M
XENE icon
24
Xenon Pharmaceuticals
XENE
$6.21B
$11.5M 1.17%
+197,759
New +$9.11M
CGON icon
25
CG Oncology
CGON
$6.62B
$11.3M 1.15%
166,349
-194,809
-54% -$11M
1
2 3 4

Similar funds

MK
MASTERINVEST Kapitalanlage Vienna $962M AUM 27.59% 1-Year Est. Return
QIM
Quantitative Investment Management Charlottesville, Virginia $963M AUM 12.95% 1-Year Est. Return
TC
TwinBeech Capital Purchase, New York $965M AUM 0.23% 1-Year Est. Return
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
PO
Paradigm Operations San Francisco, California $954M AUM 20.29% 1-Year Est. Return

Silverarc Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Silverarc Capital Management held 93 positions worth $980M, up 36% from $720M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Silverarc Capital Management deployed $316M of net new capital in Q1 2026, opening 25 new positions and adding to 16 existing holdings. Its largest new stake was Zenas BioPharma: 1,135,935 shares worth $22.2M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 96% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Abivax, an estimated $14.2M trimmed.

  • Silverarc Capital Management's largest Q1 2026 buy was Zenas BioPharma: 1,135,935 shares worth $22.2M.
  • Silverarc Capital Management added most to Monte Rosa Therapeutics in Q1 2026, an estimated $18.6M increase.
  • Silverarc Capital Management's biggest Q1 2026 reduction was Abivax, cutting an estimated $14.2M.
  • Silverarc Capital Management fully exited Viridian Therapeutics in Q1 2026, selling an estimated $10.8M.
  • Silverarc Capital Management's ten largest holdings make up 50% of its $980M portfolio in Q1 2026.
  • Silverarc Capital Management opened 25 new positions and closed 20 in Q1 2026.
  • Silverarc Capital Management's portfolio value rose 36% quarter-over-quarter to $980M.

Based on Silverarc Capital Management's 13F filing for Q1 2026, filed 14 May 2026.